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Several new chemotherapeutic tools are now available for the control of lymphatic filariasis. Combinations
of single doses of antifilarial drugs are generally superior to single drugs. The efficacy and safety of
albendazole in combination with diethylcarbamazinc (DEC) or ivermectin, for the treatment of Brugia
malayi  infection, were investigated, for the first time, in an open, hospital-based study. Fifty-one
asymptomatic microfilaraemics (with 108-4034 microfilariae/ml; median = 531) of both sexes and aged
14-70 years were randomly allocated to receive single-dose treatments of ivermectin (200 µg/kg) with
diethylcarbamazine (DEC; 6 mg/kg), ivermectin (200 µg/kg) with albendazole (400 mg), DEC (6 mg/kg)
with albendazole (400 mg), or albendazole (400 mg) alone. Albendazole alone had no effect on the
microfilarial levels at the 1-year follow-up but both groups given DEC had significantly lower mi-
crofilaraemias ( P < 0.015 and P < 0.02) than that given ivermectin with albendazole. Overall, 47%-64%
of  those  g iven  DEC but  on ly  14% of  those  g iven  ivermect in  wi th  a lbendazole  appeared  to  be
amicrofilaraemic 1 year post-treatment. The adverse reactions seen in the study were mild, transient and
qualitatively similar to those seen earlier with ivermectin and DEC. The combination of DEC and
albendazole, both well tested drugs, offers a new option for countries such as India where there is no
onchocerciasis or loiasis and where ivermectin may not be immediately available. The direct and indirect
effects of albendazole on intestinal helminths would be additional benefits.
Lymphatic filariasis is regarded as a major
health problem in many parts of the tropical
world, with recent estimates indicating that
nearly 119 million people are afflicted by the
disease (Michael et al., 1996). After mood
disorders, the disease is the most common
cause of physical morbidity (WHO, 1995).
Until recently, control of the disease was
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largely based on the use of a single drug,
diethylcarbamazine (DEC), in various regi-
mens (control of the mosquito vectors was
largely unsuccessful, for a variety of reasons).
However, several new developments in the
chemotherapy of the disease have completely
changed the outlook for its control. These
developments followed the discovery that
ivermectin, a semi-synthetic macrolide, was
effective in clearing the parasitaemias of
Wuchereria bancrofti (Kumaraswami et al.,
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1988) and Brugia malayi infections (Shenoy et
al., 1992). In a comparative study, single doses
of iverrnectin were found to be as effective as
the standard 12-day course of DEC (Ottesen
et al., 1990). These results led to a re-
examination of the older drug: DEC. Surpris-
ingly, a single dose of DEC was found to be as
effective as the standard course over 12 days
(Andrade et al., 1995). Recent studies using
ultrasound (Dreyer et al., 1995) and new
antigen-detection assays (Weil et al., 1997)
have also convincingly documented the
macrofilaricidal potential of DEC, which had
been suspected on clinical, parasitological and
histopathological grounds (Ottesen, 1985).
Furthermore, the utility of DEC-fortified salt
as a tool for effective control has now
been well documented (Gelband, 1994;
Shenoy et al., 1998b).
The superiority of combinations of iver-
mectin and DEC over either drug used alone
has been established, in the treatment of both
bancroftian (Moulia-Pelat et al., 1995) and
brugian infections (Shenoy et al., 1998a).
More recently, it has been demonstrated that
combinations of albendazole with either iver-
mectin or DEC can effectively clear the
microfilaraemias of bancroftian infections
(Addiss et al., 1997; Ismail et al., 1998). The
aim of the present study was to see if albenda-
zole, either alone or in combination with




Fifty-one individuals with Brugia malayi
microfilaraemias participated in the present,
hospital-based study. Since all the three drugs
tested-albendazole, ivermectin and DEC-
are already being used in communities, it was
decided to include (non-pregnant, non-lactat-
ing) females and children in the study, so that
these groups could also benefit from the
results. Each of the subjects (adults) or their
parents (children) gave informed consent.
None of the subjects had any clinical or labo-
ratory abnormalities other than their
microfilaraemia. The  in tens i t i es  o f  the
microfilaraemias on enrollment ranged
from 108-4064 microfilariae (mff)/ml
(median = 531 mff/ml). The subjects were
recruited after night-blood screening at special
Microfilaria Detection Camps organized by
the Filariasis Chemotherapy Unit (FCU) of
the T.D. Medical College Hospital, Alap-
puzha, India, and were residents of an area
known to be endemic for brugian filariasis.
Clinical and Laboratory Examinations
Each subject was hospitalized for 7 days in the
ward of the FCU, to permit extensive clinical
and laboratory investigations, accurate drug
administration and monitoring of any adverse
reactions (Shenoy et al., 1992, 1993, 1998a, b).
On admission, each subject was given a com-
plete physical examination, haematological
screening (haematocrit, complete blood
counts, and total and differential white-blood-
cell counts) and biochemical tests (bilirubin,
aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase and crea-
tinine leve l s )  and  sub jec ted  to  ches t
radiography and electrocardiography. Vital
signs were monitored every 4 h for the first
48 h post-treatment and then each morning
during the hospitalization. Signs and symp-
toms were graded 0 (none), 1 (mild) or 2
(severe) at each follow-up and the grades
recorded during the hospitalization were
summed to give a total score for each subject
(Shenoy et al., 1992, 1993, 1998a). All the
subjects were required to return to the hospi-
tal at frequent intervals as part of the follow-
up programme. At each visit they were
questioned about signs and symptoms and
clinically evaluated. All the biochemical tests
given on admission were repeated 2 weeks
post-treatment to evaluate the safety of the
trial drugs.
Study Design
Initially, the 51 subjects were randomly allo-
cated (using block randomization) to one of
four single-dose treatments: ivermectin
(200 µg/kg) with DEC (6 mg/kg); ivermectin
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(200 µg/kg) with albendazole (400 mg); DEC
(6 mg/kg) with albendazole (400 mg); or
albendazole (400 mg) alone. After the study
had commenced, however, the albendazole-
only treatment arm was dropped after only
three patients had been allocated to it, because
of a change in the study design. However, the
three patients continued to be followed up, in
a manner similar to the others in the study.
The drugs were administered at 08.00
hours on the third hospital day (day 3), on an
empty stomach. They were given as tablets,
each containing 50 or 100 mg DEC, 6 mg
ivermectin or 400 mg albendazole. The mean
total doses given per subject were 308 mg
DEC (5.99 mg/kg), 10.4 mg ivermectin
(201.55 µg/kg) and/or 400 mg albendazole.
Alcoholic beverages were not permitted on
days 2-10. There were no other dietary
restrictions. Severe reactions were treated
with paracetamol but no other medication was
administered for 7 days post-treatment. None
of the subjects had previously received
antifilarials and no such drugs or antiparasitic
drugs were allowed for 1 year post-treatment.
Efficacy Measurements
Microfilarial densities (mff/ml blood) were
used as indices of efficacy and were deter-
mined by diluting 1 ml heparinized venous
blood with 3 ml saline and filtering 1 ml of the
mixture through a 3-µm-pore membrane filter
(Nuclepore). The microfilariae trapped on the
filter were then counted. The pre-treatment
microfilarial density for each subject was
estimated as the mean value obtained using
three blood samples collected in the week
prior to drug administration. Microfilarial
densities were subsequently determined 1, 2,
5, 7, 14, 30, 90, 180, 270 and 360 days
post-treatment.
Statistical Methods
All microfilarial counts were logarithmically
transformed before comparison by Student’s
t-tests, and expressed as percentages of the
corresponding pre-treatment values when
appropriate.
RESULTS
The 51 subjects enrolled were aged 14-70
years. The data for six subjects were excluded
from the final analysis because job constraints
made it impossible for the subjects to adhere
to the follow-up schedule (one patient given
ivermectin with DEC, one given ivermectin
with albendazaole, and one given DEC with 
albendazole), because the subjects had
received inadvertent treatment with DEC
elsewhere during the study period (one sub-
ject given ivermectin with albendazaole, and
one given albendazole alone), or because of
emigration from the study area (one subject
given ivermectin with DEC). The data on the
remaining 45 patients who successfully com-
pleted a year of follow-up (i.e. 14 given iver-
mectin with DEC, 14 given ivermectin with
albendazole, 15 given DEC with albendazole,
and just two given albendazole alone) were
included in the efficacy analysis. [At the end
o f  t h e  p r e s e n t study, 1 year post-
treatment, each of these 45 subjects was given
albendazole with DEC (those previously
given albendazole alone) or identical treatment
to that given previously.  Each will  be
followed-up for another year.]
The age and sex distributions and the pre-
treatment microfilarial densities in the four
treatment groups are shown in the Table. The
mean pre-treatment density in the subjects
belonging to the ivermectin + DEC group was
significantly higher than the mean densities
for the other three groups (P < 0.01 for each),
which were similar.
Microfilarial Clearance
The pattern of microfilarial clearance in each
of the treatment groups is illustrated in the
Figure. The combination of ivermectin and
DEC achieved a mean clearance of 99.56% by
12 h post-treatment, reaching 100% by that
time in five subjects. Ivermectin with albenda-
zole gave a mean clearance of only 78.87% by
12 h post-treatment and all the subjects given
this combination remained microfilaraemic
at that time. In the DEC + albendazole group
the mean clearance 12 h post-treatment was
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TABLE
The ages, sexes and treatments of the 51 subjects and the levels of their microfilaraemias pre-treatment
No. of subjects Geometric mean
Age range microfilaraemias and (ranges)
Treatment Males  Females  A l l (years) (microfilariae/ml)
Ivermectin + diethylcarbamazine 13 3 16 16-55 912 (236-4064)
Ivermectin + albendazole 14 2 16 14-70 482 (108-1981)
Diethylearbamazine + albendazole 14 2 16 15-65 374 (145-978)
Albendazole 3 0 3 46-48 306 (181-747)
96.16% but only one subject was ami-
crofilaraemic. There was practically no
clearance of microfilariae in the three patients
given albendazole alone.
Microfilaraemias in those given iver-
mectin + DEC dropped rapidly and remained
low throughout the follow-up year (with den-
sities only 0.3%-4.2% of those seen pre-treat-
ment). The decline in microfilarial densities in
those given ivermectin with albendazole was
more gradual, reaching a minimum (2.2% of
the pre-treatment value) 30 days post-
treatment; thereafter the levels increased
steadily until the end of the follow-up year.
The minimum mean microfilarial density seen
in those given DEC + albendazole occurred
12 h post-treatment, the mean densities then
slowly rose until 7 days post-treatment (to
14.6% of the pre-treatment level) before
gradually falling back down. In the small
group that received albendazole alone, the
mean values fluctuated widely but remained
high (82.6%-148% of the mean pre-treatment
level).
At the end of the first year, the mean
microfilarial levels in the two groups given
DEC were low (0.33% of the pre-treatment
value for ivermectin + DEC and 1.51% for
DEC + albendazole). Although one was not
statistically different from the other (P > 0.5),
both were significantly lower than the level
recorded at the same time in those given
ivermectin + albendazole (P < 0.020 for each).
One year post-treatment, nine (64%) of the
14 patients given ivermectin + DEC, seven
(47%) of the 15 given DEC + albendazole but
only two (14%) of the 14 given iver-
mectin + albendazole and neither of those
who received albendazole alone were
amicrofilaraemic.
A d v e r s e  R e a c t i o n s   
The data for all 51 subjects who were initially
enrolled on the study were included in the
analysis of adverse reactions since all were
available for investigation until 1 month post-
treatment, by which time all side-effects had
disappeared. Adverse effects first appeared
about 12 h post-treatment but generally
cleared within 48 h. The most frequently
reported reactions were fever, headache, myal-
gia, chills and lethargy. Most did not require
any treatment other than paracetamol.
Adverse reactions were reported by all 16
subjects given ivermectin + DEC, 12 (75%)
of the 16 given ivermectin + albendazole,
15 (94%) of those given DEC + albendazole
and two (67%) of the three subjects who
received albendazole alone. Those given
albendazole alone only complained of mild
myalgia. The mean (SD.) adverse-reaction
scores for the groups were as follows:
8.6 (5.7) for ivermectin + DEC; 3.9 (5.1)
for ivermectin + albendazole; 3.8 (2.1) for
DEC + albendazole; and 3.3 (1.7) for albenda-
zole alone. The mean score for those given
ivermectin + DEC was significantly higher
than those for the subjects who received
ivermectin + albendazolc (P < 0.021) or
DEC + albendazole (P < 0.003).
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Days post-treatment
Fig .  Microf i la r ia l  c lea rance  in  those  t rea ted  wi th  ivcrmcct in  +  d ie thy lcarbamazine  (0) ,  ive r -
mectin + albendazolc (O), albendazole + diethylearbamazinc (m) or albendazolc alone (A).
DISCUSSION
The chemotherapeutic tools available for the
control of lymphatic filariasis have rapidly
increased in number during the last decade.
Effective parasite control can now be achieved
using single annual doses of DEC or iver-
mectin, either alone or in combination
(Ottescn and Ramachandran, 1995). DEC-
fortified salt is another option for the control
of bancroftian (Gelband, 1994) and brugian
infections (Shenoy et al., 1998b). New diag-
nostic tools, such as DNA probes (WHO,
1994) and tests to detect daytime-circulating
antigen (Weil et al., 1997), which are poten-
tially useful in monitoring the success of con-
trol programmes, have also been developed.
These advances have been responsible for the
identification of lymphatic filariasis as one of
only six potentially eradicable diseases (Anon.,
1993) and the recent passage of a World
Health Assembly resolution to eliminate this
disease as a public-health problem (Ottesen,
1998).
The recent observations that albendazole, in
combination with either ivermectin (Addiss
et al., 1997; Ismail et al., 1998) or DEC (Ismail
et al., 1998), can suppress bancroftian
microfilaracmia for prolonged periods has
opened up the possibility of using this drug in
large-scale control programmes. Since alben-
dazolc is a broad-spectrum anthclmintic with
proven efficacy against a range of intestinal
nematodes, its use would have the additional
benefit of clearing these parasites from the
treated individuals. Use of albendazole has
particular appeal to those involved in school
health programmes aimed at control of
geohelminth infections, since it would help
the children treated to get rid of their filarial
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parasites early and thus prevent morbidity
later (Addiss et al., 1997).
The present study appears to be the first to
investigate the efficacy and safety of albenda-
zole, either alone or in combination with other
antifilarial drugs, in the control of brugian
filariasis. There are known to be significant
differences between brugian and bancroftian
infections in terms of the efficacy of, and
tolerance to their treatment with antifilarial
drugs, whether these are used singly (Shenoy
et al., 1992), in combinations (Shenoy et al.,
1998a) or as fortified salt (Shenoy et al.,
1998b). The present results again highlight the
differences in responses of these two infec-
tions and also the need for developing appro-
priate control strategies for brugian filariasis.
The most rapid and best sustained sup-
pression of microfilaraemia was seen in the
group treated with ivermectin and DEC and
was similar to that seen in an earlier study in
which the same combination was used
(Shcnoy et al., 1998a). However, at the end of
1 year there was no difference between the
microfilarial clearance in this group and
that in the subjects who received
DEC + albendazole (P > 0.5). The pattern of
clearance caused by the two DEC-containing
regimens was similar: a rapid decline in counts
in the first 12 h post-treatment followed by a
marginal rise (more pronounced in the
DEC + albendazole group) between 2 to 14
days post-treatment. This effect was prob-
ably DEC-driven, reflecting an init ial
microfilaricidal action followed by a
macrofilaricidal one (Shenoy et al., 1998a).
The pattern of clearance produced by iver-
mectin + albendazole (a steady decline in
microfilarial densities, for 30 days, followed by
a slow but steady rise until the end of the
1-year follow-up), was similar to that observed
when patients with brugian infections were
treated with ivermectin alone (Shenoy et al.,
1992). Albendazole, when given alone as a
single, 400-mg dose, clearly had no effect on
microfilarial levels. It therefore appears that it
is the other drug (DEC or ivermectin) that
plays the major role when the microfilaraemias
of brugian infections are cleared using drug
combinations including albendazole. More
importantly, combinations of DEC with either
ivermectin or albendazole are superior to a
combination of ivermectin and albendazole in
decreasing the intensity and prevalence of
microfilaraemia 1 year post-treatment.
The adverse reactions seen in the present
study were qualitatively similar to those seen
when ivermectin and DEC arc given either
singly or in combination (Shenoy et al., 1992,
1998a). The mean adverse-reaction score was
highest in the group that received iver-
mectin + DEC. Unfortunately, however,
because of the randomness of the allocation
process, this group was also the one that had
significantly higher microfilaraemias pre-
treatment than the other treatment. groups.
Despite this limitation, the relatively high
adverse-reaction scores of those given iver-
mectin + DEC probably reflect the systemic
response to the rapid clearance of micro-
filaraemia caused by this drug combination.
No unusual side-effects, such as postural
hypotension or the occurrence of the ‘string
sign’, were seen during the present study,
although Shenoy et al. (1998a) encountered
these with a combination of ivermectin and
DEC. No adverse reactions indicative of a
macrofilaricidal effect (such as the develop-
ment of nodules, lymphadenopathy, or a ‘scro-
tal syndrome’) were produced by any of the
present treatments.
The present results highlight several issues
relating to the mode of action of albendazole
when combined with DEC or ivermectin for
the treatment of microfilaraemias. Although
albendazole undoubtedly has useful activity
against intestinal helminths (Addiss et al.,
1997), its role as an antifilarial in combination
regimens with ivermectin or DEC needs to be
examined carefully; it is unclear how it poten-
tiates the antifilarial action of the other two
drugs. Although albendazole used alone in
repeated, high doses has been shown to be
macrofilaricidal in bancroftian filariasis
(Jayakody et al., 1993), the drug had no appar-
ent effect on B. malayi in the present study.
In contrast, DEC has been shown to have
marked macrofilaricidal and microfilaricidal
properties (Ottesen, 1985; Dreyer et al., 1995;
Weil et al., 1997). Although ivermectin rapidly
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and effectively clears microfilaraemias and
prevents their re-appearance for prolonged
periods, there is no evidence to indicate that
ivermectin has any macrofilaricidal activity.
Since DEC + albendazole was at least as
effective at clearing microfilaraemias as iver-
mectin + DEC in the present study, albenda-
zole presumably enhances the activity of
DEC. It would be interesting to observe the
long-term effects (i.e. those occurring beyond
1 year) of DEC + albendazole, since the pat-
tern of microfilarial clearance achieved with
this combination in the present study (see
Fig.) indicates that it may be even more effec-
tive than ivermectin + albendazole.
It is unfortunate that there are no markers
to detect macrofilaricidal activity in antifilarial
drugs when they are used against brugian
infections. It is now possible to determine the
adulticidal effect of drugs used, singly or in
combination, in bancroftian filariasis, using
either ultrasound (Dreyer et al., 1995) or anti-
gen levels (Weil et al., 1997; Ismail et al.,
1998). However, adult B. malayi do not
appear to be detectable by ultrasound, and no
corresponding antigen-detection tests are
currently available for brugian infections
(unpubl. obs.). Conclusions regarding the
macrofilaricidal effects of any drug used
against brugian filariasis must therefore be
based on indirect evidence, such as long-term
suppression of microfilaraemia.
The present observations have two import-
ant implications for programmes to control
lymphatic filariasis in areas where brugian
infections occur. Firstly, the combination of
DEC and albendazole should be an efficient
tool for the control of the microfilaraemias of
brugian infections, being at least as effective as
ivermectin with DEC. It will also be a partic-
ularly attractive tool in national programmes
that target schoolchildren and young adults,
because of the additional benefits of using
albendazole. In addition to its well docu-
mented effects on intestinal helminths and the
anaemia that. they produce (WHO, 1996),
albendazole offers other benefits ‘beyond
filariasis’. These include gains in height and
weight of treated children (Beach et al., 1998),
improved performance at school (Nokes et al.,
1992), and the increased productivity of the
adults in treated populations (Stephenson et
al., 1993). Secondly, and perhaps more impor-
tantly, the findings offer a new option for
countries, such as India, which may not have
ready access to ivermectin in the near future.
In these countries, where DEC can safely be
used since there is no onchocerciasis or loiasis,
use of DEC + albendazole should provide all
the advantages of a ‘combination therapy’ with
the added advantage of using two drugs that
are already used extensively and that have an
excellent safety record. However, further,
large-scale clinical trials will be needed before
this combination can b e  u s e d  u n d e r
programme conditions.
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